A5064785619- Virus-based gene therapy research
- Cancer Research and Treatments
- CAR-T cell therapy research
- RNA Interference and Gene Delivery
- Glioma Diagnosis and Treatment
- Hepatitis B Virus Studies
- interferon and immune responses
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Toxin Mechanisms and Immunotoxins
- Cancer, Hypoxia, and Metabolism
- Cytomegalovirus and herpesvirus research
- Viral Infections and Immunology Research
- Galectins and Cancer Biology
Navarre Institute of Health Research
2022-2024
Clinica Universidad de Navarra
2022-2024
Universidad de Navarra
2022-2024
The outcomes of metastatic and nonresponder pediatric osteosarcoma patients are very poor have not improved in the last 30 years. These tumors harbor a highly immunosuppressive environment, making existing immunotherapies ineffective. Here, we evaluated use Semliki Forest virus (SFV) vectors expressing galectin-3 (Gal3) inhibitors as therapeutic tools, since both inhibition Gal3, which is involved immunosuppression metastasis, virotherapy based on SFV been demonstrated to reduce tumor...
Pediatric high-grade gliomas (pHGGs), including diffuse midline (DMGs), are aggressive pediatric tumors with one of the poorest prognoses. Delta-24-RGD and ONC201 have shown promising efficacy as single agents for these tumors. However, combination both has not been evaluated.
<h3>Background</h3> Viroimmunotherapy is an emerging biotherapeutic strategy utilizing oncolytic viruses (OVs) to mediate tumor destruction through direct oncolysis and instigation of anti-tumor immunity. There growing interest in viroimmunotherapy for pediatric brain tumors due its ability enhance immune responses non-inflamed tumors. Our lab developed the adenovirus Delta-24-RGD, which has been tested Phase I clinical trial (NCT03178032) as front-line therapy brainstem diffuse midline...
Abstract Diffuse midline gliomas (DMGs) are very aggressive central nervous system tumors that occur mainly in children and adolescents. Most DMGs develop the brainstem, but they can also be found thalamus spinal cord, latter comprising 4% of all DMGs. Despite advances current treatments, outcome for DMG patients remains extremely poor. The success immunotherapy other encourages its translation to DMGs, which understanding tumor immune microenvironment (TIME) is imperative. field counts with...
Abstract Diffuse midline gliomas (DMGs) are among the most frequent and lethal pediatric tumors. The standard of care for DMGs is palliative, resulting in a median survival 12 months. Viroimmunotherapy an emerging alternative treatment these Our group developed platform oncolytic adenoviruses that was translated to clinic. Specifically, Delta-24-RGD recently tested Phase I clinical trial patients with newly diagnosed DMG (NCT03178032) encouraging results. To further stimulate immune arm this...
Abstract Diffuse Midline Gliomas (DMG) are very aggressive brain tumors that arise in the brainstem of children. The prognosis these patients is still dismal, with an overall survival less than one year. DMG poorly infiltrated by immune system, and therefore this project, we propose use oncolytic adenovirus Delta-24-RGDOX to enhance antitumor response. based on Delta-24-RGD platform incorporates OX40 ligand (OX40L). binding OX40L leads co-stimulation CD4 CD8 cells, generating effector memory...
Abstract With a 2-year survival less than 20%, Diffuse Intrinsic Pontine Glioma (DIPG) is the principal cause of pediatric death. Despite recent advances in current treatments, outcome for children with DIPGs remains dismal. Since approval T-VEC melanoma by FDA, oncolytic adenoviruses have emerged as promising therapeutic strategy brain tumors. Thus, our group launched first world clinical trial phase I adenovirus Delta-24-RGD (DNX-2401 clinic) newly diagnosed DIPG (NCT03178032), which has...
Abstract Purpose of Study: Diffuse Midline Gliomas (DMG) are aggressive pediatric brain tumors that arise in the brainstem children, with a peak incidence between 5-10 years old. The median survival DMG patients is only 9 months, being leading cause death caused by tumor. On this project we set to characterize efficacy Delta-24-RGDOX, an oncolytic adenovirus based on Delta-24-RGD platform, which has demonstrated safety and therapeutic benefit different tumors, armed ligand OX40. binding OX40...
Abstract Purpose of the work: Pediatric High Grade Gliomas (pHGGs), including Diffuse Midline (DMGs), are very aggressive solid tumors developed during childhood with a poor overall survival underscoring need for effective treatments. The adenovirus Delta-24RGD and imipridone ONC201 have demonstrated safety effectiveness in preclinical models clinical trials. Thus, we evaluated therapeutic efficacy Delta-24-RGD/ONC201 combination analyzed possible changes tumor microenvironment pHGGs DMGs....
<h3>Background</h3> Within Diffuse Midline Gliomas, Intrinsic Pontine Glioma (DIPG) is the principal cause of non-accidental pediatric deaths. Although gold-standard treatments have improved, outcome for children with DIPGs remains poor pointing to need alternative therapies. In this sense, we previously demonstrated that oncolytic adenovirus Delta-24-RGD (which has already shown safety and feasibility in DIPG patients) able recruit T cells into tumor. However, such as T-lymphocyte...